|Bid||8.58 x 800|
|Ask||8.75 x 900|
|Day's Range||8.41 - 9.85|
|52 Week Range||7.43 - 23.58|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.67|
On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Begin in First Half of 2022 AN2 Board Strengthened through Appointment of Key Industry Executives MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical com
MENLO PARK, Calif., May 09, 2022--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors.
The collective valuation of the 10 biggest first quarter exits of 2022 among local companies was less than a tenth of that of the top 10 from the same period last year.